Microneedle-array patch with pH-sensitive formulation for glucose-responsive insulin delivery
- 5 January 2021
- journal article
- research article
- Published by Tsinghua University Press in Nano Research
- Vol. 14 (8) , 2689-2696
Abstract
Glucose-responsive insulin delivery systems show great promise to improve therapeutic outcomes and quality of life for people with diabetes. Herein, a new microneedle-array patch containing pH-sensitive insulin-loaded nanoparticles (NPs) (SNP(I)) together with glucose oxidase (GOx)- and catalase (CAT)-loaded pH-insensitive NPs (iSNP(G+C)) is constructed for transcutaneous glucose-responsive insulin delivery. SNP(I) are prepared via double emulsion from a pH-sensitive amphiphilic block copolymer, and undergo rapid dissociation to promote insulin release at a mild acidic environment induced by GOx in iSNP(G+C) under hyperglycemic conditions. CAT in iSNP(G+C) can further consume excess H2O2 generated during GOx oxidation, and thus reduce the risk of inflammation toward the normal skin. The in vivo study on type 1 diabetic mice demonstrates that the platform can effectively regulate blood glucose levels within normal ranges for a prolonged period.Keywords
This publication has 51 references indexed in Scilit:
- Recent progress in design and preparation of glucose-responsive insulin delivery systemsJournal of Controlled Release, 2020
- Advances in bioresponsive closed-loop drug delivery systemsInternational Journal of Pharmaceutics, 2018
- Complications With Insulin Pump Therapy vs Insulin Injection Therapy—ReplyJAMA, 2018
- Type 2 diabetesThe Lancet, 2017
- Type 1 diabetesThe Lancet, 2014
- Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes MellitusAnnals of Internal Medicine, 2012
- Genetics, pathogenesis and clinical interventions in type 1 diabetesNature, 2010
- Frequency and predictors of hypoglycaemia in Type 1 and insulin‐treated Type 2 diabetes: a population‐based studyDiabetic Medicine, 2005
- Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic NephropathyJAMA, 2003
- Insulins today and beyondThe Lancet, 2001